rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alkermes plc -

ALKS · Nasdaq

Health CarePharmaceuticalsJust started moving

ALKS stood above a rising 150-day average in 33 of the last 52 weekly readings, including each of the last 1 week. It is 0.9% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
1 in a row
Industry in uptrend
32% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$20.0M
Officials’ trades on record
8
Institutions holding
391 (+32)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

20 Apr – 19 Oct
26%34%43%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$11.7M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

8 disclosed lines: House 2, Senate 0, executive 6; 2 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k29 Sep 2026filed 12 Oct 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$15k–$50k30 Jul 2026filed 4 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k15 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k15 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k30 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k26 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k26 Jan 2026filed 14 May 2026

Insiders

Buy orders, 12 months0
Sale orders, 12 months29
Buyers · sellers0 · 7
WhoDidSharesTraded
David Joseph GaffinEVP, CLO, Alkermes, Inc.sold2,034at $41.032 Oct 2026filed 2 Oct 2026
David Joseph GaffinEVP, CLO, Alkermes, Inc.sold2,034at $48.013 Sep 2026filed 3 Sep 2026
Craig C. HopkinsonEVP R&D, Chief Medical Officersold9,000at $46.991 Sep 2026filed 1 Sep 2026
Christian Todd NicholsSVP, Chief Commercial Officersold6,912at $49.1917 Aug 2026filed 17 Aug 2026
Christian Todd NicholsSVP, Chief Commercial Officersold664at $49.6517 Aug 2026filed 17 Aug 2026
David Joseph GaffinEVP, CLO, Alkermes, Inc.sold2,034at $48.583 Aug 2026filed 3 Aug 2026
Craig C. HopkinsonEVP R&D, Chief Medical Officersold9,000at $48.583 Aug 2026filed 3 Aug 2026
Nancy Lynn Md SnydermanDirectorsold44,472at $50.353 Aug 2026filed 3 Aug 2026
David Joseph GaffinEVP, CLO, Alkermes, Inc.sold2,034at $54.036 Jul 2026filed 6 Jul 2026
Craig C. HopkinsonEVP R&D, Chief Medical Officersold8,300at $51.461 Jul 2026filed 1 Jul 2026
Craig C. HopkinsonEVP R&D, Chief Medical Officersold700at $52.131 Jul 2026filed 1 Jul 2026
Christopher I. WrightDirectorsold2,000at $45.1012 Jun 2026filed 12 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders391+32 on the quarter
New · exited88 · 55
Reported value$8.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202629,235,739$1.5B+921,329+3.3%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 202610,012,267$524.6M00.0%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20269,490,818$497.3M-20,294−0.2%
STATE STREET CORPreduced · filed 7 Aug 20269,160,575$480.0M-304,711−3.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,515,025$393.7M+87,628+1.2%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 20266,460,928$338.5M+300,500+4.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,477,876$234.7M+295,609+7.1%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 20264,194,873$219.8M-327,505−7.2%
Deep Track Capital, LPadded · filed 14 Aug 20264,000,000$209.6M+409,677+11.4%
AMERICAN CENTURY COMPANIES INCreduced · filed 12 Aug 20263,954,239$207.2M-2,117,864−34.9%
31 Mar 2023 – 30 Jun 2026
230308385Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Joshua Reed Company insiderSVP, Chief Financial Officer · last 8 Oct 20260 · 0
Anne Clem Whitaker Company insiderDirector · last 7 Oct 20260 · 0
David Joseph Gaffin Company insiderEVP, CLO, Alkermes, Inc. · last 2 Oct 20260 · 16
Gilbert Ray Cisneros, Jr. HouseCA31 · last 29 Sep 20262 · 0
Craig C. Hopkinson Company insiderEVP R&D, Chief Medical Officer · last 1 Sep 20260 · 26
Christian Todd Nichols Company insiderSVP, Chief Commercial Officer · last 17 Aug 20260 · 8
Blair Curtis Jackson Company insiderPresident & CEO, Alkermes plc · last 5 Aug 20260 · 2
nancy lynn snyderman Company insiderDirector · last 3 Aug 20261 · 1
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20263 · 3
Christopher I. Wright Company insiderDirector · last 12 Jun 20260 · 1
Samuel Joseph Parisi Company insiderVP, Finance (Interim PAO) · last 29 May 20260 · 6
Brian P. McKeon Company insiderDirector · last 21 May 20261 · 0

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202586.7%
Operating profit marginFY 2025 · to 31 Dec 202517.2%
Free cash flow marginFY 2025 · to 31 Dec 202532.5%
Return on capital employedFY 2025 · to 31 Dec 202513.1%
Cash conversionFY 2025 · to 31 Dec 2025215%
Research spendFY 2025 · to 31 Dec 202522.0%
Share count trendFY 2025 · to 20 Feb 20260.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$388.6M
Free cash flowFY 2025 · to 31 Dec 2025$480.3M

Analyst forecasts

No analyst forecasts yet.